180 related articles for article (PubMed ID: 22479349)
1. Estimating individual exposure to malaria using local prevalence of malaria infection in the field.
Olotu A; Fegan G; Wambua J; Nyangweso G; Ogada E; Drakeley C; Marsh K; Bejon P
PLoS One; 2012; 7(3):e32929. PubMed ID: 22479349
[TBL] [Abstract][Full Text] [Related]
2. Lack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya.
Ibison F; Olotu A; Muema DM; Mwacharo J; Ohuma E; Kimani D; Marsh K; Bejon P; Ndungu FM
PLoS One; 2012; 7(12):e52939. PubMed ID: 23300828
[TBL] [Abstract][Full Text] [Related]
3. A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria.
Murungi LM; Kamuyu G; Lowe B; Bejon P; Theisen M; Kinyanjui SM; Marsh K; Osier FH
Vaccine; 2013 Aug; 31(37):3936-42. PubMed ID: 23800539
[TBL] [Abstract][Full Text] [Related]
4. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.
Dodoo D; Atuguba F; Bosomprah S; Ansah NA; Ansah P; Lamptey H; Egyir B; Oduro AR; Gyan B; Hodgson A; Koram KA
Malar J; 2011 May; 10():108. PubMed ID: 21529376
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria.
Mugyenyi CK; Elliott SR; McCallum FJ; Anders RF; Marsh K; Beeson JG
PLoS One; 2013; 8(7):e68304. PubMed ID: 23861883
[TBL] [Abstract][Full Text] [Related]
6. Interaction between maternally derived antibodies and heterogeneity in exposure combined to determine time-to-first Plasmodium falciparum infection in Kenyan infants.
Reynaldi A; Dent AE; Schlub TE; Ogolla S; Rochford R; Davenport MP
Malar J; 2019 Jan; 18(1):19. PubMed ID: 30670032
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1.
Johnson AH; Leke RG; Mendell NR; Shon D; Suh YJ; Bomba-Nkolo D; Tchinda V; Kouontchou S; Thuita LW; van der Wel AM; Thomas A; Stowers A; Saul A; Zhou A; Taylor DW; Quakyi IA
Infect Immun; 2004 May; 72(5):2762-71. PubMed ID: 15102786
[TBL] [Abstract][Full Text] [Related]
8. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
[TBL] [Abstract][Full Text] [Related]
9. Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya.
Weber GE; White MT; Babakhanyan A; Sumba PO; Vulule J; Ely D; John C; Angov E; Lanar D; Dutta S; Narum DL; Horii T; Cowman A; Beeson J; Smith J; Kazura JW; Dent AE
Sci Rep; 2017 Dec; 7(1):16821. PubMed ID: 29203846
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya.
Agak GW; Bejon P; Fegan G; Gicheru N; Villard V; Kajava AV; Marsh K; Corradin G
Vaccine; 2008 Apr; 26(16):1963-71. PubMed ID: 18342997
[TBL] [Abstract][Full Text] [Related]
11. Malaria transmission and individual variability of the naturally acquired IgG antibody against the Plasmodium vivax blood-stage antigen in an endemic area in Brazil.
Costa EMF; Amador ECC; Silva ES; Alvarenga CO; Pereira PE; Póvoa MM; Cunha MG
Acta Trop; 2020 Sep; 209():105537. PubMed ID: 32454033
[TBL] [Abstract][Full Text] [Related]
12. RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study.
Dobaño C; Ubillos I; Jairoce C; Gyan B; Vidal M; Jiménez A; Santano R; Dosoo D; Nhabomba AJ; Ayestaran A; Aguilar R; Williams NA; Díez-Padrisa N; Lanar D; Chauhan V; Chitnis C; Dutta S; Gaur D; Angov E; Asante KP; Owusu-Agyei S; Valim C; Gamain B; Coppel RL; Cavanagh D; Beeson JG; Campo JJ; Moncunill G
BMC Med; 2019 Aug; 17(1):157. PubMed ID: 31409398
[TBL] [Abstract][Full Text] [Related]
13. Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission.
Zakeri S; Babaeekhou L; Mehrizi AA; Abbasi M; Djadid ND
Am J Trop Med Hyg; 2011 Jun; 84(6):944-50. PubMed ID: 21633032
[TBL] [Abstract][Full Text] [Related]
14. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.
Osier FH; Fegan G; Polley SD; Murungi L; Verra F; Tetteh KK; Lowe B; Mwangi T; Bull PC; Thomas AW; Cavanagh DR; McBride JS; Lanar DE; Mackinnon MJ; Conway DJ; Marsh K
Infect Immun; 2008 May; 76(5):2240-8. PubMed ID: 18316390
[TBL] [Abstract][Full Text] [Related]
15. Serological markers for monitoring historical changes in malaria transmission intensity in a highly endemic region of Western Kenya, 1994-2009.
Wong J; Hamel MJ; Drakeley CJ; Kariuki S; Shi YP; Lal AA; Nahlen BL; Bloland PB; Lindblade KA; Were V; Otieno K; Otieno P; Odero C; Slutsker L; Vulule JM; Gimnig JE
Malar J; 2014 Nov; 13():451. PubMed ID: 25416454
[TBL] [Abstract][Full Text] [Related]
16. High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms.
Versiani FG; Almeida ME; Melo GC; Versiani FO; Orlandi PP; Mariúba LA; Soares LA; Souza LP; da Silva Balieiro AA; Monteiro WM; Costa FT; del Portillo HA; Lacerda MV; Nogueira PA
Malar J; 2013 Aug; 12():294. PubMed ID: 23977965
[TBL] [Abstract][Full Text] [Related]
17. Serologically defined variations in malaria endemicity in Pará state, Brazil.
Cunha MG; Silva ES; Sepúlveda N; Costa SP; Saboia TC; Guerreiro JF; Póvoa MM; Corran PH; Riley E; Drakeley CJ
PLoS One; 2014; 9(11):e113357. PubMed ID: 25419900
[TBL] [Abstract][Full Text] [Related]
18. Malaria hotspots defined by clinical malaria, asymptomatic carriage, PCR and vector numbers in a low transmission area on the Kenyan Coast.
Kangoye DT; Noor A; Midega J; Mwongeli J; Mkabili D; Mogeni P; Kerubo C; Akoo P; Mwangangi J; Drakeley C; Marsh K; Bejon P; Njuguna P
Malar J; 2016 Apr; 15():213. PubMed ID: 27075879
[TBL] [Abstract][Full Text] [Related]
19. Plasmodium falciparum Protein Microarray Antibody Profiles Correlate With Protection From Symptomatic Malaria in Kenya.
Dent AE; Nakajima R; Liang L; Baum E; Moormann AM; Sumba PO; Vulule J; Babineau D; Randall A; Davies DH; Felgner PL; Kazura JW
J Infect Dis; 2015 Nov; 212(9):1429-38. PubMed ID: 25883384
[TBL] [Abstract][Full Text] [Related]
20. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
